CNSX:VP Vodis Pharmaceuticals (VP) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free VP Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume51,582 shsAverage Volume1,714 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Vodis Pharmaceuticals alerts: Email Address Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Vodis Pharmaceuticals Stock (CNSX:VP)Vodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana. It operates in Canada and the United States. The company is based in Delta, Canada.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. VP Stock News HeadlinesMarch 27, 2024 | tmcnet.comCOVETRUS® TRANSFORMS PRESCRIPTION MANAGEMENT FOR VETERINARY PRACTICES WITH INTRODUCTION OF vRxPro™March 22, 2024 | msn.comStates' drug pricing boards off to a slow startApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 25, 2024 | msn.comVerrica Pharmaceuticals Set to Discuss Q4 and Full-Year 2023 Financial Results in Upcoming Conference CallFebruary 7, 2024 | markets.businessinsider.comAbivax appoints Ana Sharma as Vice President, Global Head of QualityJanuary 24, 2024 | markets.businessinsider.comMedicines360 Appoints Lisa David as Chair of the Board of Directors, Strengthening its Commitment to Women’s HealthDecember 14, 2023 | msn.comDr Reddy's becomes sole Indian pharma player to make it to Dow Jones Sustainability World Index 2023December 7, 2023 | msn.comBiden warns Big Pharma: Make your drugs cheaper or the US government will override your patentsApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…December 7, 2023 | abcnews.go.comThe White House is threatening the patents of high-priced drugs developed with taxpayer dollarsDecember 1, 2023 | msn.comAmneal Pharma in pact with Strides to launch generic VascepaNovember 6, 2023 | markets.businessinsider.comAnavex Life Sciences Appoints Senior VP of Regulatory AffairsOctober 14, 2023 | foxnews.comXpeng's vice president suspended amid corruption investigation in supply chain managementOctober 9, 2023 | marketwatch.comLexicon Pharmaceuticals Up 20% on Express Scripts Designation for Inpefa Heart DrugOctober 4, 2023 | markets.businessinsider.comStrengthening of vertical integration: Exyte completes acquisition of pure media specialist IntegaSeptember 19, 2023 | newsweek.comVice PresidentAugust 28, 2023 | usatoday.comRepublican voters want Donald Trump. And his vice president? How about more Trump?August 22, 2023 | news.yahoo.comTeva Pharmaceuticals to pay $225M fine to settle price-fixing chargesAugust 1, 2023 | msn.comVertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call TranscriptMay 29, 2023 | news.yahoo.comWhat has Kamala Harris done as vice president?March 31, 2023 | nytimes.comVice President Kamala Harris: Latest NewsFebruary 1, 2023 | yahoo.comIonis announces GSK has advanced bepirovirsen into Phase 3 developmentJanuary 27, 2023 | yahoo.comZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)January 12, 2023 | marketwatch.comThe way Medicare will negotiate down prescription drug prices takes shapeJanuary 10, 2023 | msn.comGlenmark Pharmaceuticals launches congestive heart failure injection in United StatesJanuary 7, 2023 | msn.comMore families facing price shocks for lifesaving children's medicationsJanuary 6, 2023 | cnn.comFDA to review preventative option for RSV in infants, developers saySee More Headlines Receive VP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vodis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCNSX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCNSX:VP CUSIPN/A CIKN/A Webvodis.ca Phone778-990-8985FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Brian R. Gusko (Age 52)Advisor Mr. Mark Lotz B.B.A.C.A., CPA, Interim CEO, CFO & DirectorKey Competitors45525 (CUR.TO)TSE:CURCanada House Wellness GroupCNSX:CHVDirexion Daily Healthcare Bull 3X SharesCNSX:CUREMatica EnterprisesCNSX:MMJPreveCeutical MedicalCNSX:PREVView All Competitors VP Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Vodis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vodis Pharmaceuticals investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP). How do I buy shares of Vodis Pharmaceuticals? Shares of VP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (CNSX:VP) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vodis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
